NCT03944447: OMNI-Can

Outcomes Mandate National Integration With Cannabis as Medicine

Status unknown Phase 2 Last updated 2 June 2022

What this trial tests

Phase 2 trial testing Cannabis, Medical in Chronic Pain in 200,000 participants. Status unknown.

Timeline

1 December 2018

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	OMNI Medical Services, LLC
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200,000
Start date	1 December 2018
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	17 locations across United States

Drugs / interventions tested

• Cannabis, Medical — full drug profile →
• RYAH-Medtech Inhaler

Conditions studied

• Chronic Pain — all drugs for Chronic Pain →
• Chronic Pain Syndrome — all drugs for Chronic Pain Syndrome →
• Chronic Pain Due to Injury — all drugs for Chronic Pain Due to Injury →
• Chronic Pain Due to Trauma — all drugs for Chronic Pain Due to Trauma →

Sponsor

OMNI Medical Services, LLC — full company profile →

Who can join

7 and older, any sex, with Chronic Pain or Chronic Pain Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.
   Ning Q, Wu D, Wang X, Xi D, et al · · 2022 · cited 64× · PMID 35197452 · DOI 10.1038/s41392-022-00907-1
2. New Insights into Oxidative Stress and Inflammatory Response in Neurodegenerative Diseases.
   Scarian E, Viola C, Dragoni F, Di Gerlando R, et al · · 2024 · cited 61× · PMID 38473944 · DOI 10.3390/ijms25052698
3. Traditional Herbal Medicines, Bioactive Metabolites, and Plant Products Against COVID-19: Update on Clinical Trials and Mechanism of Actions.
   Alam S, Sarker MMR, Afrin S, Richi FT, et al · · 2021 · cited 61× · PMID 34122096 · DOI 10.3389/fphar.2021.671498
4. Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19.
   Pereira GJDS, Leão AHFF, Erustes AG, Morais IBM, et al · · 2021 · cited 36× · PMID 33920748 · DOI 10.3390/ijms22084067
5. Cannabinoids in Breast Cancer: Differential Susceptibility According to Subtype.
   Almeida CF, Teixeira N, Correia-da-Silva G, Amaral C. · · 2021 · cited 26× · PMID 35011388 · DOI 10.3390/molecules27010156
6. The role of basket trials in drug development for neurodegenerative disorders.
   Cummings J, Montes A, Kamboj S, Cacho JF. · · 2022 · cited 21× · PMID 35614479 · DOI 10.1186/s13195-022-01015-6
7. Phytopharmaceuticals mediated Furin and TMPRSS2 receptor blocking: can it be a potential therapeutic option for Covid-19?
   Palit P, Chattopadhyay D, Thomas S, Kundu A, et al · · 2021 · cited 20× · PMID 33380375 · DOI 10.1016/j.phymed.2020.153396
8. <i>In silico</i> investigation and potential therapeutic approaches of natural products for COVID-19: Computer-aided drug design perspective.
   Rahman MM, Islam MR, Akash S, Mim SA, et al · · 2022 · cited 18× · PMID 36072227 · DOI 10.3389/fcimb.2022.929430